zonisamide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2872	68291-97-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: zonisamide exceglan excegram excegran zonegran	an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents, blocks sodium channels and reduces voltage-dependent, transient inward currents (T-type Ca2+ currents), consequently stabilizing neuronal membranes and suppressing neuronal hypersynchronization Molecular weight: 212.22 Formula: C8H8N2O3S CLOGP: -0.36 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 86.19 ALOGS: -2.01 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

zonisamide
exceglan
excegram
excegran
zonegran

an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents, blocks sodium channels and reduces voltage-dependent, transient inward currents (T-type Ca2+ currents), consequently stabilizing neuronal membranes and suppressing neuronal hypersynchronization

Molecular weight: 212.22
Formula: C8H8N2O3S
CLOGP: -0.36
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 86.19
ALOGS: -2.01
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.20	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.80 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	22 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	40.39 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
March 27, 2000	FDA	EISAI INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	750.44	14.44	433	11221	122621	46551787
Epilepsy	200.31	14.44	104	11550	23634	46650774
Drug reaction with eosinophilia and systemic symptoms	192.37	14.44	109	11545	29439	46644969
Multiple-drug resistance	134.42	14.44	42	11612	2523	46671885
Status epilepticus	131.69	14.44	66	11588	13913	46660495
Atonic seizures	117.73	14.44	28	11626	592	46673816
Generalised tonic-clonic seizure	117.19	14.44	77	11577	27045	46647363
Stevens-Johnson syndrome	105.19	14.44	68	11586	23229	46651179
Drug eruption	83.57	14.44	57	11597	21272	46653136
Irritability	72.24	14.44	59	11595	28887	46645521
Focal dyscognitive seizures	64.91	14.44	25	11629	2803	46671605
Cognitive disorder	63.67	14.44	61	11593	36822	46637586
Oculomucocutaneous syndrome	63.01	14.44	13	11641	138	46674270
Aggression	62.37	14.44	49	11605	22695	46651713
Product substitution issue	60.85	14.44	41	11613	14990	46659418
Ataxia	56.40	14.44	38	11616	13892	46660516
Choroidal effusion	54.18	14.44	14	11640	420	46673988
Partial seizures	54.17	14.44	26	11628	4984	46669424
Drug withdrawal convulsions	54.07	14.44	18	11636	1323	46673085
Suicidal behaviour	53.91	14.44	21	11633	2427	46671981
Petit mal epilepsy	51.63	14.44	22	11632	3198	46671210
Therapeutic response unexpected	50.21	14.44	37	11617	15579	46658829
Somnolence	48.47	14.44	115	11539	156406	46518002
Dyskinesia	46.47	14.44	46	11608	28879	46645529
Psychotic disorder	45.98	14.44	41	11613	22580	46651828
Hyperammonaemic encephalopathy	43.63	14.44	17	11637	1965	46672443
Drug ineffective	43.52	14.44	303	11351	677535	45996873
Hepatic function abnormal	41.52	14.44	47	11607	34374	46640034
Tonic convulsion	41.25	14.44	14	11640	1092	46673316
Infantile spasms	40.33	14.44	10	11644	253	46674155
Rheumatoid arthritis	40.28	14.44	6	11648	240209	46434199
Ovarian granulosa-theca cell tumour	39.81	14.44	7	11647	28	46674380
Vestibular migraine	37.65	14.44	8	11646	99	46674309
Epileptic psychosis	33.20	14.44	6	11648	29	46674379
Dyspnoea	32.65	14.44	49	11605	515499	46158909
Calculus urinary	32.19	14.44	11	11643	876	46673532
Drug interaction	31.73	14.44	117	11537	202977	46471431
Diplopia	31.42	14.44	31	11623	19374	46655034
Brown tumour	31.07	14.44	6	11648	44	46674364
Intentional overdose	29.70	14.44	56	11598	64888	46609520
Depressed level of consciousness	29.59	14.44	47	11607	47522	46626886
Mood altered	29.30	14.44	25	11629	12982	46661426
Placental infarction	29.04	14.44	8	11646	308	46674100
Diarrhoea	28.42	14.44	61	11593	559541	46114867
Therapeutic product effective for unapproved indication	28.41	14.44	6	11648	72	46674336
Myoclonic epilepsy	27.94	14.44	10	11644	913	46673495
Toxic epidermal necrolysis	27.85	14.44	31	11623	22247	46652161
Lichen planus	27.66	14.44	12	11642	1821	46672587
Suicidal ideation	27.51	14.44	50	11604	56332	46618076
Delusion	26.22	14.44	22	11632	11166	46663242
Depressed mood	25.10	14.44	36	11618	33283	46641125
Depression	24.90	14.44	96	11558	170008	46504400
Hallucination, visual	24.31	14.44	26	11628	17847	46656561
Encapsulating peritoneal sclerosis	22.99	14.44	7	11647	385	46674023
Hallucination, auditory	22.86	14.44	20	11634	10736	46663672
Upper respiratory tract inflammation	22.84	14.44	12	11642	2783	46671625
Arthralgia	22.70	14.44	35	11619	364568	46309840
Therapeutic product ineffective for unapproved indication	22.55	14.44	6	11648	202	46674206
Migraine	22.22	14.44	52	11602	69974	46604434
Anticonvulsant drug level decreased	21.61	14.44	9	11645	1235	46673173
Hallucination	21.51	14.44	42	11612	49909	46624499
Erythema multiforme	20.53	14.44	18	11636	9686	46664722
Anticonvulsant drug level increased	20.47	14.44	9	11645	1411	46672997
Neuroleptic malignant syndrome	20.33	14.44	19	11635	11103	46663305
Drug level increased	20.25	14.44	24	11630	18417	46655991
Dysmetria	19.85	14.44	6	11648	322	46674086
Myoclonus	19.73	14.44	21	11633	14331	46660077
Drug resistance	19.73	14.44	23	11631	17345	46657063
Lymphocyte stimulation test positive	19.73	14.44	7	11647	623	46673785
Nystagmus	19.44	14.44	14	11640	5685	46668723
Exposure during pregnancy	19.15	14.44	65	11589	108147	46566261
Suicide attempt	18.71	14.44	42	11612	54994	46619414
Developmental delay	18.70	14.44	8	11646	1174	46673234
Ureterolithiasis	18.61	14.44	9	11645	1753	46672655
Disturbance in attention	18.01	14.44	30	11624	31530	46642878
Insomnia	17.87	14.44	85	11569	164839	46509569
Abnormal behaviour	17.72	14.44	24	11630	21034	46653374
Sinus arrhythmia	17.62	14.44	8	11646	1352	46673056
Myopia	17.47	14.44	8	11646	1379	46673029
Placental disorder	17.35	14.44	8	11646	1401	46673007
Altered state of consciousness	17.25	14.44	25	11629	23323	46651085
Product complaint	17.16	14.44	18	11636	12083	46662325
Pregnancy	17.13	14.44	27	11627	27110	46647298
Coma	17.08	14.44	42	11612	58307	46616101
Bipolar disorder	16.58	14.44	14	11640	7163	46667245
Agitation	16.34	14.44	40	11614	55375	46619033
Sudden unexplained death in epilepsy	16.27	14.44	5	11649	284	46674124
Joint swelling	15.90	14.44	11	11643	166062	46508346
Human herpes virus 6 serology positive	15.81	14.44	4	11650	110	46674298
Electrocardiogram PR prolongation	15.75	14.44	6	11648	653	46673755
Abortion spontaneous	15.61	14.44	34	11620	43612	46630796
Hypothermia	15.31	14.44	17	11637	12166	46662242
Therapeutic response changed	15.05	14.44	6	11648	736	46673672
Retinogram abnormal	15.05	14.44	4	11650	134	46674274
Encephalocele	14.72	14.44	4	11650	146	46674262
Congenital tracheomalacia	14.70	14.44	3	11651	30	46674378
Renal hypoplasia	14.44	14.44	3	11651	33	46674375

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	508.20	17.66	318	7631	98157	29846372
Status epilepticus	245.69	17.66	97	7852	10975	29933554
Epilepsy	133.98	17.66	77	7872	20092	29924437
Generalised tonic-clonic seizure	117.60	17.66	70	7879	19481	29925048
Drug reaction with eosinophilia and systemic symptoms	107.25	17.66	76	7873	28412	29916117
Stevens-Johnson syndrome	100.75	17.66	61	7888	17495	29927034
Aggression	93.93	17.66	78	7871	36829	29907700
Somnolence	80.59	17.66	113	7836	96650	29847879
Partial seizures	76.52	17.66	31	7918	3736	29940793
Choroidal effusion	60.91	17.66	13	7936	154	29944375
Calculus urinary	57.95	17.66	19	7930	1252	29943277
Focal dyscognitive seizures	57.35	17.66	19	7930	1294	29943235
Multiple-drug resistance	55.63	17.66	23	7926	2918	29941611
Oculomucocutaneous syndrome	54.51	17.66	12	7937	166	29944363
Toxic epidermal necrolysis	52.12	17.66	41	7908	17899	29926630
Drug eruption	48.66	17.66	39	7910	17487	29927042
Drug ineffective	48.46	17.66	198	7751	340189	29604340
Dyspnoea	47.18	17.66	15	7934	333280	29611249
Nystagmus	47.06	17.66	23	7926	4315	29940214
Nephrolithiasis	44.36	17.66	43	7906	24767	29919762
Hepatic function abnormal	42.52	17.66	54	7895	41891	29902638
Myoclonus	42.10	17.66	32	7917	13280	29931249
Delusion	40.54	17.66	30	7919	11959	29932570
Irritability	39.43	17.66	39	7910	23011	29921518
Pneumonia aspiration	38.87	17.66	49	7900	37731	29906798
Product substitution issue	38.24	17.66	27	7922	10008	29934521
Abnormal behaviour	35.98	17.66	39	7910	25584	29918945
Ataxia	35.03	17.66	27	7922	11435	29933094
Hyperammonaemic encephalopathy	33.45	17.66	14	7935	1830	29942699
Psychotic disorder	32.42	17.66	34	7915	21481	29923048
Drug withdrawal convulsions	32.28	17.66	12	7937	1147	29943382
Neonatal pneumonia	32.13	17.66	7	7942	92	29944437
Altered state of consciousness	30.95	17.66	32	7917	19887	29924642
Neonatal hypotension	30.56	17.66	7	7942	117	29944412
Salivary hypersecretion	30.33	17.66	21	7928	7545	29936984
Sudden unexplained death in epilepsy	30.03	17.66	9	7940	441	29944088
Anticonvulsant drug level increased	29.16	17.66	12	7937	1503	29943026
Infantile spasms	28.99	17.66	8	7941	291	29944238
Condition aggravated	28.69	17.66	91	7858	137775	29806754
Hallucination	25.15	17.66	46	7903	49013	29895516
Congenital inguinal hernia	24.99	17.66	6	7943	124	29944405
Aminoaciduria	24.94	17.66	6	7943	125	29944404
Lymphocyte stimulation test positive	24.07	17.66	9	7940	874	29943655
Dyskinesia	23.53	17.66	29	7920	21805	29922724
Hypotension	23.46	17.66	12	7937	200553	29743976
Atonic seizures	23.32	17.66	6	7943	166	29944363
Arthralgia	23.31	17.66	4	7945	135787	29808742
Cytotoxic oedema	22.60	17.66	6	7943	188	29944341
Parkinsonism	21.94	17.66	17	7932	7252	29937277
Angle closure glaucoma	21.92	17.66	8	7941	726	29943803
Depressive symptom	21.76	17.66	10	7939	1635	29942894
Drug interaction	21.40	17.66	107	7842	199461	29745068
Death	21.37	17.66	39	7910	357244	29587285
Liver disorder	20.74	17.66	32	7917	29690	29914839
Foetal exposure during pregnancy	20.72	17.66	36	7913	36835	29907694
Product lot number issue	20.27	17.66	4	7945	31	29944498
Implant site pruritus	19.63	17.66	3	7946	3	29944526
Disseminated intravascular coagulation	18.54	17.66	26	7923	22145	29922384
Implant site rash	18.41	17.66	3	7946	6	29944523
Assisted delivery	18.41	17.66	3	7946	6	29944523
Electroencephalogram abnormal	18.28	17.66	10	7939	2364	29942165

Pharmacologic Action:

Source	Code	Description
ATC	N03AX15	NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Other antiepileptics
FDA CS	M0020790	Sulfonamides
FDA MoA	N0000000235	Carbonic Anhydrase Inhibitors
FDA PE	N0000008486	Decreased Central Nervous System Disorganized Electrical Activity
FDA EPC	N0000175753	Anti-epileptic Agent
MeSH PA	D000927	Anticonvulsants
MeSH PA	D002121	Calcium Channel Blockers
MeSH PA	D000077264	Calcium-Regulating Hormones and Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D049990	Membrane Transport Modulators
CHEBI has role	CHEBI:22586	antioxidants
CHEBI has role	CHEBI:35470	cns agent
CHEBI has role	CHEBI:35623	antiepileptic
CHEBI has role	CHEBI:50267	protective agents
FDA MoA	N0000185503	P-Glycoprotein Inhibitors

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Partial Epilepsy Treatment Adjunct	indication
Suicidal thoughts	contraindication	6471006
Agranulocytosis	contraindication	17182001	DOID:12987
Mood swings	contraindication	18963009
Depressive disorder	contraindication	35489007
Metabolic acidosis	contraindication	59455009
Diarrhea	contraindication	62315008
Psychotic disorder	contraindication	69322001
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007
Diminished sweating	contraindication	111980002
Disease of liver	contraindication	235856003	DOID:409
Aplastic anemia	contraindication	306058006	DOID:12449
Severe chronic obstructive pulmonary disease	contraindication	313299006
Fever	contraindication	386661006
Surgical procedure	contraindication	387713003

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.47	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium channel protein type 1 subunit alpha	Ion channel	P35498	SCN1A_HUMAN	BLOCKER			WOMBAT-PK	CHEMBL
Carbonic anhydrase 5A, mitochondrial	Enzyme	P35218	CAH5A_HUMAN		Ki	7.70	CHEMBL
Carbonic anhydrase 14	Enzyme	Q9ULX7	CAH14_HUMAN		Ki	5.28	CHEMBL
Carbonic anhydrase 7	Enzyme	P43166	CAH7_HUMAN		Ki	6.93	CHEMBL
Carbonic anhydrase V	Enzyme	P35218 Q9Y2D0	CAH5A_HUMAN CAH5B_HUMAN		Ki	7.69	CHEMBL
Carbonic anhydrase 4	Enzyme	P22748	CAH4_HUMAN		Ki	5.07	CHEMBL
Carbonic anhydrase 5B, mitochondrial	Enzyme	Q9Y2D0	CAH5B_HUMAN		Ki	5.22	CHEMBL
Amine oxidase [flavin-containing] B	Enzyme	P27338	AOFB_HUMAN		Ki	5.51	CHEMBL
Carbonic anhydrase 13	Enzyme	Q8N1Q1	CAH13_HUMAN		Ki	6.37	CHEMBL
Carbonic anhydrase 6	Enzyme	P23280	CAH6_HUMAN		Ki	7.05	CHEMBL
Carbonic anhydrase 9	Enzyme	Q16790	CAH9_HUMAN		Ki	8.30	WOMBAT-PK
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN		Ki	7.25	WOMBAT-PK
Voltage-dependent T-type calcium channel subunit alpha-1G	Ion channel	O43497	CAC1G_HUMAN				WOMBAT-PK
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		Ki	6.99	WOMBAT-PK
Carbonic anhydrase 12	Enzyme	O43570	CAH12_HUMAN	INHIBITOR	Ki	4.96	IUPHAR
Carbonic anhydrase	Unclassified		C0IX24_9CNID		Ki	6.19	CHEMBL
Delta carbonic anhydrase	Unclassified		Q5U9J1_THAWE		Ki	6.39	CHEMBL
Carbonic anhydrase 2	Unclassified		Q3I4V7_CRYNV		Ki	6.01	CHEMBL
Carbonic anhydrase	Enzyme		CAN_YEAST		Ki	6.97	CHEMBL
Carbonic anhydrase	Enzyme		CYNT_HELPY		Ki	6.66	CHEMBL
Carbonic anhydrase 15	Enzyme		CAH15_MOUSE		Ki	6.20	CHEMBL
Alpha carbonic anhydrase	Unclassified		B5SU02_9CNID		Ki	6.59	CHEMBL
Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase	Enzyme		P96878_MYCTU		Ki	6.68	CHEMBL
Carbonic anhydrase 3	Enzyme		CAH3_BOVIN		Ki	5.07	CHEMBL
Astrosclerin-3	Unclassified		A6YCJ1_9METZ		Ki	6.78	CHEMBL
Amine oxidase [flavin-containing] B	Enzyme		AOFB_RAT		Ki	5.54	CHEMBL
Amine oxidase [flavin-containing]	Unclassified		AOF_DANRE		Ki	4.51	CHEMBL
Carbonic anhydrase	Enzyme		CAN_CANAL		Ki	7.46	CHEMBL
Beta-carbonic anhydrase 1	Enzyme		MTCA1_MYCTU		Ki	4.54	CHEMBL
Carbonic anhydrase 2	Enzyme		MTCA2_MYCTU		Ki	6.06	CHEMBL
Carbonic anhydrase	Unclassified		Q5TU56_ANOGA		Ki	6.58	CHEMBL
Carbonic anhydrase	Enzyme		Q6FTL6_CANGA		Ki	6.94	CHEMBL

External reference:

ID	Source
4021224	VUID
N0000148668	NUI
D00538	KEGG_DRUG
4021224	VANDF
C1710707	UMLSCUI
CHEBI:10127	CHEBI
ZON	PDB_CHEM_ID
CHEMBL750	ChEMBL_ID
D000078305	MESH_DESCRIPTOR_UI
5734	PUBCHEM_CID
5575	INN_ID
459384H98V	UNII
7047	IUPHAR_LIGAND_ID
DB00909	DRUGBANK_ID
261708	RXNORM
31898	MMSL
73622	MMSL
8781	MMSL
d04527	MMSL
008137	NDDF
125693002	SNOMEDCT_US
398762003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
zonisamide	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8266	CAPSULE	100 mg	ORAL	ANDA	23 sections
ZONISAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-539	CAPSULE	100 mg	ORAL	ANDA	16 sections
ZONISAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-724	CAPSULE	25 mg	ORAL	ANDA	13 sections
ZONISAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-155	CAPSULE	100 mg	ORAL	ANDA	28 sections
ZONISAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-654	CAPSULE	50 mg	ORAL	ANDA	28 sections
Zonisamide	HUMAN PRESCRIPTION DRUG LABEL	1	29300-428	CAPSULE	25 mg	ORAL	ANDA	12 sections
Zonisamide	HUMAN PRESCRIPTION DRUG LABEL	1	29300-429	CAPSULE	50 mg	ORAL	ANDA	12 sections
Zonisamide	HUMAN PRESCRIPTION DRUG LABEL	1	29300-430	CAPSULE	100 mg	ORAL	ANDA	12 sections
Zonisamide	HUMAN PRESCRIPTION DRUG LABEL	1	31722-228	CAPSULE	100 mg	ORAL	ANDA	25 sections
ZONISAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	33261-843	CAPSULE	100 mg	ORAL	ANDA	13 sections
ZONISAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	35356-143	CAPSULE	100 mg	ORAL	ANDA	16 sections
Zonisamide	HUMAN PRESCRIPTION DRUG LABEL	1	43063-932	CAPSULE	25 mg	ORAL	ANDA	22 sections
Zonisamide	HUMAN PRESCRIPTION DRUG LABEL	1	50268-816	CAPSULE	100 mg	ORAL	ANDA	26 sections
Zonisamide	HUMAN PRESCRIPTION DRUG LABEL	1	51407-137	CAPSULE	25 mg	ORAL	ANDA	22 sections
Zonisamide	HUMAN PRESCRIPTION DRUG LABEL	1	51407-138	CAPSULE	50 mg	ORAL	ANDA	22 sections
Zonisamide	HUMAN PRESCRIPTION DRUG LABEL	1	51407-139	CAPSULE	100 mg	ORAL	ANDA	22 sections
zonisamide	HUMAN PRESCRIPTION DRUG LABEL	1	53217-301	CAPSULE	100 mg	ORAL	ANDA	24 sections
Zonisamide	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5789	CAPSULE	100 mg	ORAL	ANDA	14 sections
Zonisamide	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6221	CAPSULE	50 mg	ORAL	ANDA	14 sections
ZONISAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	55648-945	CAPSULE	25 mg	ORAL	ANDA	13 sections
ZONISAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	55648-946	CAPSULE	50 mg	ORAL	ANDA	13 sections
ZONISAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	55648-990	CAPSULE	100 mg	ORAL	ANDA	13 sections
Zonegran	Human Prescription Drug Label	1	59212-680	CAPSULE	100 mg	ORAL	NDA	26 sections
Zonegran	Human Prescription Drug Label	1	59212-681	CAPSULE	25 mg	ORAL	NDA	26 sections
Zonisamide	Human Prescription Drug Label	1	59651-378	CAPSULE	25 mg	ORAL	ANDA	23 sections
Zonisamide	Human Prescription Drug Label	1	59651-379	CAPSULE	50 mg	ORAL	ANDA	23 sections
Zonisamide	Human Prescription Drug Label	1	59651-380	CAPSULE	100 mg	ORAL	ANDA	23 sections
Zonisamide	HUMAN PRESCRIPTION DRUG LABEL	1	60687-230	CAPSULE	100 mg	ORAL	ANDA	24 sections
ZONISAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	61919-275	CAPSULE	50 mg	ORAL	ANDA	11 sections
Zonisamide	HUMAN PRESCRIPTION DRUG LABEL	1	61919-591	CAPSULE	50 mg	ORAL	ANDA	14 sections